PPA
STOK icon

Parametric Portfolio Associates’s Stoke Therapeutics STOK Stock Holding History

Parametric Portfolio Associates’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,708
Closed -$416K – 3593
2021
Q1 		$416K Buy
10,708
+2,857
+36% +$163K ﹤0.01% 3581
2020
Q4 		$486K Buy
7,851
+1,208
+18% +$55.4K ﹤0.01% 3395
2020
Q3 		$222K Buy
+6,643
New +$190K ﹤0.01% 3612

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Parametric Portfolio Associates's STOK Position: Q2 2021 in Review

Parametric Portfolio Associates sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 10,708 shares — an estimated $416K sold.

Parametric Portfolio Associates first reported a position in STOK in Q3 2020 and held it in 3 quarters. The position peaked at $486K in Q4 2020. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

  • Parametric Portfolio Associates reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 10,708 Stoke Therapeutics shares in Q2 2021, an estimated $416K.
  • Parametric Portfolio Associates first reported a position in Stoke Therapeutics in Q3 2020 and held it in 3 quarters.
  • Parametric Portfolio Associates's Stoke Therapeutics position peaked at $486K in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on Parametric Portfolio Associates's 13F filing for Q2 2021, filed 13 Aug 2021.